Fig. 2
Association between SLCO4A1-AS1 and clinical characteristics. (A) SLCO4A1-AS1 expression levels were elevated in gliomas. The data were obtained from TCGA and GTEx datasets. (B) SLCO4A1-AS1 expression levels in glioma and normal tissues based on GSE44971. (C, D) Expression levels of SLCO4A1-AS1 in different WHO grades in the TCGA and CGGA datasets. (E, F) Distribution of SLCO4A1-AS1 in different ages in TCGA and CGGA datasets. (G, H) Relationship between the SLCO4A1-AS1 expression level and IDH mutation status in the TCGA and CGGA datasets. (I, J) Expression of SLCO4A1-AS1 in the 1p/19q codeletion (codel) and non-codel groups in TCGA and CGGA datasets. (K) SLCO4A1-AS1 is upregulated in recurrent types. The data were obtained from CGGA dataset. (L) SLCO4A1-AS1 expression is increased in MES types in the TCGA dataset. (M) Proportions of glioma samples with various subtypes. The data were obtained from TCGA dataset. (N) MES signature of GSEA. The data were obtained from TCGA dataset. (O) Differential expression analysis of MES markers (FN1, TIMP1, CD44, SERPINE1 and CHI3L1) and PN markers (NCAM1 and ASCL1) in the high SLCO4A1-AS1 and low SLCO4A1-AS1 expression groups. The data were obtained from TCGA dataset. (P, Q) Differential expression analysis of MES signature markers in TCGA (P) and CGGA (Q). Significant statistical differences between the two groups were assessed using the Mann–Whitney test. Significant statistical differences among more than the two groups were assessed using the Kruskal–Wallis test. The data were obtained from TCGA and CGGA datasets. NS, not statistically significant; * P < 0.05; ** P < 0.01; *** P < 0.001.
